Suppr超能文献

[疫苗与发展中国家]

[Vaccines and developing countries].

作者信息

Bjune G

机构信息

Avdeling for Vaksine, Statens Institutt for Folkehelse, Oslo.

出版信息

Tidsskr Nor Laegeforen. 1991 May 10;111(12):1496-9.

PMID:2042182
Abstract

Infectious diseases are the main cause of mortality and morbidity in developing countries. The Expanded Programme on Immunization, initiated by WHO in 1974, now reaches 60 mill. a year at a cost of less than 2 US $ per immunized child, and saves 2.2 mill. lives annually. The present vaccines, however, have significant shortcomings. Measles vaccine is given too late to prevent the large number of deaths occurring in the first year of life. Attenuated polio vaccine has to be given three times and inherits the risk of "vaccine palsy" and revertion to virulence. Tetanus vaccine given to children does not prevent neonatal tetanus, the main cause of tetanus casualties. BCG does not control spread of tuberculosis. Vaccines given parenterally involve some risk of spread of HIV, and some potentially useful vaccines are too expensive for developing countries. By only modest investments modern gene technology could give improved and new vaccines which would potentially save 20 mill. lives a year. Particularly promising is the recent development of multi-vaccine-vectors. However, poor prospects for profit in developing countries and patent "swapping" by commercial producers severely hamper development in the vaccine field.

摘要

传染病是发展中国家死亡和发病的主要原因。世界卫生组织于1974年发起的扩大免疫规划,目前每年惠及6000万人,每个接种儿童的成本不到2美元,每年挽救220万人的生命。然而,目前的疫苗存在重大缺陷。麻疹疫苗接种时间过晚,无法预防一岁以内儿童大量死亡。减毒脊髓灰质炎疫苗必须接种三次,存在“疫苗性麻痹”和毒力回复的风险。给儿童接种的破伤风疫苗无法预防新生儿破伤风,而新生儿破伤风是破伤风致死的主要原因。卡介苗无法控制结核病传播。注射用疫苗存在传播艾滋病毒的风险,而且一些潜在有用的疫苗对发展中国家来说过于昂贵。只需适度投资,现代基因技术就能研发出改进型和新型疫苗,每年有可能挽救2000万人的生命。特别有前景的是多疫苗载体的最新进展。然而,在发展中国家盈利前景不佳以及商业生产商的专利“交换”严重阻碍了疫苗领域的发展。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验